Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study

References

• Milsom I, Kaplan SA, Coyne KS, et al. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 2012;80:90-6
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014;33:17-30
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95
   Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20
   PubMed Web of Science ®Google Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
   PubMed Web of Science ®Google Scholar
• Matza LS, Thompson CL, Krasnow J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005;24:215-25
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson C, et al. The responsiveness of the OAB-q among OAB patient subgroups. Neurourol Urodyn 2007;26:196-203
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005;14:849-55
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. J Urol 2006;176:627-32
   PubMed Web of Science ®Google Scholar
• Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health 2005;8:495-505
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-74
   PubMed Web of Science ®Google Scholar
• Nozawa Y, Kato D, Tabuchi H, et al. Safety and effectiveness of mirabegron in patients with overactive bladder in a real-world clinical setting: a Japanese post-marketing study. Low Urin Tract Symptoms 2016. doi: 10.1111/luts.12148
   Web of Science ®Google Scholar
• Kato D, Tabuchi H, Uno S. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: interim (1-year) report from a Japanese post-marketing surveillance study. Low Urin Tract Symptoms 2017. doi: 10.1111/luts.12188
   Web of Science ®Google Scholar
• Katoh T, Kuwamoto K, Kato D, et al. Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study. Int J Urol 2016;23:1009-15
   PubMed Web of Science ®Google Scholar
• Kato D, Uno S, Van Schyndle J, et al. Persistence and adherence to overactive bladder medications in Japan: a large nationwide real-world analysis. Int J Urol 2017;24:757-64
   PubMed Web of Science ®Google Scholar
• Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J 2015;9:343-50
   PubMed Web of Science ®Google Scholar
• Nitti VW, Rovner ES, Franks B, et al. Persistence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits 2016;8:e25-33
   Web of Science ®Google Scholar
• Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol 2017;72:389-99
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment report. Betmiga: EMA; 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002388/WC500137308.pdf. [last accessed 11 October 2017]
   Google Scholar
• Gravas S, Bach T, Bachmann A, et al. European Association of Urology Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS) including benign prostatic obstruction; 2015. European Association of Urology. Available at: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-Neurogenic-Male-LUTS-Guidelines-2015-v2.pdf. [last accessed 11 October 2017]
   Google Scholar
• Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol 2015;193:921-6
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int 2015;116:612-22
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 2015;67:577-88
   PubMed Web of Science ®Google Scholar
• Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 2017;120:562-75
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 2016;70:136-45
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305
   PubMed Web of Science ®Google Scholar
• Castro-Diaz D, Chapple CR, Hakimi Z, et al. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. Qual Life Res 2015;24:1719-27
   PubMed Web of Science ®Google Scholar
• Nazir J, Maman K, Neine ME, et al. Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom. Value Health 2015;18:783-90
   PubMed Web of Science ®Google Scholar
• Nazir J, Posnett J, Walker A, et al. Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service. J Med Econ 2015;18:390-7
   PubMed Web of Science ®Google Scholar
• Odeyemi IA, Dakin HA, O’Donnell RA, et al. Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract 2006;60:949-58
   PubMed Web of Science ®Google Scholar
• Pindoria N, Malde S, Nowers J, et al. Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn 2017;36:404-8
   PubMed Web of Science ®Google Scholar
• Duckett J, Balachandran A. Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. Int Urogynecol J 2016;27:1163-7
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26
   PubMed Web of Science ®Google Scholar